Clinical trials: Motor Neurone Disease
Amyotrophic Lateral Sclerosis (ALS)
Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of FHND1002 granules in healthy adult volunteers.
- Trial name
- FHND1002-Ⅰ (NCT06782958)
- Testing
- 50mg FHND1002, 100mg FHND1002, 150 mg FHND1002
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Prostatic Neoplasm
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
This study will evaluate an experimental drug called EZN-4176 to determine the anticancer effects when it is given to patients with an advanced form of prostate cancer called castration-resistant prostate cancer (CRPC).
- Trial name
- NCT01337518
- Testing
- EZN-4176
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Prostate Cancer
An Open Label Prostate Cancer Study in Japanese Patients
The primary aim of study is to gain an initial assessment of safety and tolerability of AZD3514 in Japanese patients together with assessing Pharmacokinetics (PK) and gaining a preliminary assessment of anti-tumour action.
- Trial name
- NCT01351688
- Testing
- AZD3514
- Where
- 2 sites in Japan
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Amyotrophic Lateral Sclerosis
CuATSM Compared With Placebo for Treatment of ALS/MND
Multicenter, randomized, double-blind, placebo controlled study to assess the tolerabilty and efficacy of CuATSM in patients with ALS/MND.
- Trial name
- NCT04082832
- Testing
- Cu(II)ATSM
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- Collaborative Medicinal Development Pty Limited
Amyotrophic Lateral Sclerosis
Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
This study provides an opportunity for subjects in the REFALS (3119002; NCT03505021) study to continue treatment with oral levosimendan.
- Trial name
- REFALS-ES (NCT03948178)
- Testing
- Levosimendan
- Where
- 79 sites in United States, Australia and 12 more
- Volunteers
- 227 people
- Sponsor
- Orion Corporation, Orion Pharma
Metastatic Castration-resistant Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- rechARge (NCT06764485)
- Testing
- BMS-986365, Enzalutamide, Abiraterone
- Where
- 227 sites in United States, Argentina and 24 more
- Volunteers
- 960 people
- Sponsor
- Celgene
Amyotrophic Lateral Sclerosis
Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis
The purpose of this study is to determine the safety and tolerability of intramuscular injections of VM202 at different injection sites in people with amyotrophic lateral sclerosis.
- Trial name
- NCT02039401
- Testing
- VM202
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Helixmith Co., Ltd.
Spinal Muscular Atrophy
An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)
An open-label, multi-part, first-in-human study of oral branaplam in infants with Type 1 spinal muscular atrophy. The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD)…
- Trial name
- NCT02268552
- Testing
- branaplam
- Where
- 14 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
- Trial name
- ADOREXT (NCT05866926)
- Testing
- FAB122
- Where
- Spain
- Volunteers
- 201 people
- Sponsor
- Ferrer Internacional S.A.
Amyotrophic Lateral Sclerosis (ALS)
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
- Trial name
- UNITE-ALS (NCT07023835)
- Testing
- 50 mg Usnoflast, 75 mg Usnoflast
- Where
- 49 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- Zydus Therapeutics Inc.
ALS (Amyotrophic Lateral Sclerosis)
A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a study of transplantation of Astrocytes derived from human embryonic stem cells, in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03482050
- Testing
- AstroRx
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- Kadimastem
Primary Lateral Sclerosis, Adult, 1
"Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis"
This Individual Patient Expanded Access IND has been created as requested by an 83-year-old man who suffers Primary Lateral Sclerosis and for which the drugs currently approved are not providing an improvement over the…
- Trial name
- NCT04825613
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Amyotrophic Lateral Sclerosis
Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
The purpose of the study is to evaluate the effects of the investigational drug, SB-509 on progression of the disease in subjects with ALS
- Trial name
- ALS (NCT00748501)
- Testing
- SB-509
- Where
- 6 sites in United States
- Volunteers
- 45 people
- Sponsor
- Sangamo Therapeutics
Amyotrophic Lateral Sclerosis
Regulatory T Cells for Amyotrophic Lateral Sclerosis
Phase 1 Safety Run-in Study of 6 patients followed by Phase 1b Randomized, Double Blind, Placebo Control Trial of CK0803, neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells in additional 60 patients…
- Trial name
- REGALS (NCT05695521)
- Testing
- CK0803, Excipient
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Cellenkos, Inc.
Metastatic Castration Resistant Prostate Cancer
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies.
- Trial name
- NCT05241613
- Testing
- AC176
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Accutar Biotechnology Inc
ALS (Amyotrophic Lateral Sclerosis), ALS
Kamlanoflast In Amyotrophic Lateral Sclerosis
This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied.
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), ALS, Neuro-Degenerative Disease, Neuro-Degenerative Diseases
- Trial name
- NCT07396818
- Testing
- Kamlanoflast
- Volunteers
- 40 people
- Sponsor
- Inflammasome Therapeutics
Spinal Muscular Atrophy
Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy
The purpose of this trial is to evaluate the safety and tolerability of intrathecal administration of onasemnogene abeparvovec-xioi in infants and children with Spinal Muscular Atrophy with 3 copies of SMN2 and deletion of SMN1.
- Trial name
- STRONG (NCT03381729)
- Testing
- Onasemnogene Abeparvovec-xioi
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Novartis Gene Therapies
Muscular Atrophy, Spinal
A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
A global study of oral risdiplam in pre-symptomatic participants with spinal muscular atrophy (SMA).
- Trial name
- Rainbowfish (NCT03779334)
- Testing
- Risdiplam
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Spinal Muscular Atrophy Type II
Exoskeleton Impact on the Quality of Life on Patients With Spinal Muscular Atrophy
The purpose of this study is to evaluate the impact of the use of a pediatric exoskeleton on the quality of life of children, specifically in the psychological and care dimensions.
- Trial name
- NCT05416034
- Testing
- Use of the ATLAS 2025 exoskeleton at home
- Where
- Spain
- Volunteers
- 3 people
- Sponsor
- MarsiBionics
Amyotrophic Lateral Sclerosis
Dexpramipexole SAD/MAD Study
This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID dexpramipexole in healthy volunteers.
- Trial name
- NCT01449578
- Testing
- Dexpramipexole
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences